login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Avinger’s Ocelot catheter is CE marked


Thursday, 29 Sep 2011 11:21

Avinger has received CE mark approval for Ocelot ― a peripheral catheter system used with real-time Optical Coherence Tomography (OCT) for the treatment of peripheral artery disease.


According to Avinger, medical professionals, for the first time ever, will have access to a therapeutic device that incorporates real time intravascular guidance by using Ocelot’s Lightbox console as an adjunct to fluoroscopy.


“Ocelot CE mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I have been working on uniting intravascular guidance with therapeutic products for 30 years and I am humbled that we have been able to achieve this at Avinger,” said John B Simpson, Avinger’s founder and CEO.


Avinger is currently enrolling patients in the VISTA study ― a single-centre, non-randomised registry designed to evaluate the safety and efficacy of Ocelot in patients with peripheral artery disease. The registry is being developed in Paraguay, with Adrian Ebner of Sanitorio Italiano in Asunción, as the principal investigator.


European comercialisation of Ocelot has already begun. The first three commercial cases are scheduled to be performed in Italy and Germany in late September and early October.

 




Add New Comment

Most popular


First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

CIRSE 2014 audience needs more evidence before they support drug-elution in the superficial femoral artery
Friday, 26 Sep 2014
The audience in the CIRSE 2014 “Controversies in superficial femoral artery treatment” session failed to endorse two motions pertaining to drug-elution in this anatomical segment in the annual ... CIRSE 2014 audience needs more evidence before they support drug-elution in the superficial femoral artery

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Features


Selective transarterial chemo embolization in lung cancer
Wednesday, 19 Nov 2014
Embolization therapy combined with infusion of antineoplastic agents offers considerable improvement of symptoms for patients, with far fewer complications than systemic chemotherapy, writes Shinichi ... Selective transarterial chemo embolization in lung cancer

Multidisciplinary panel recommends early revascularisation of diabetic foot to save legs
Tuesday, 04 Nov 2014
Delays in revascularisation of diabetic foot in the UK directly relate to legs being lost to amputation. Early referral to interventionists is of critical importance and interventional radiologists ... Multidisciplinary panel recommends early revascularisation of diabetic foot to save legs

Profiles


José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions